Myriad Genetics Inc

NASDAQ: MYGN
$17.41
-$0.26 (-1.5%)
Closing Price on November 8, 2024

MYGN Stock Chart and Intraday Price

MYGN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Address 320 WAKARA WAY, SALT LAKE CITY, UT, US
Fiscal Year End June
Latest Quarter 12/31/2023
Market Cap 1,993.43M USD
Shares Outstanding 89,875,000
Myriad Genetics Inc is a pioneer in genetic testing and precision medicine, offering a wide range of molecular diagnostic tests. These tests are crucial in the fields of oncology, women's health, and pharmacogenomics, helping to assess risks for hereditary cancers and guide therapy decisions for various cancers including breast, ovarian, and prostate. Additionally, Myriad Genetics provides tests for prenatal screening and mental health medication guidance, collaborating with notable institutions like Illumina and Memorial Sloan Kettering Cancer Center. Founded in 1992, the company is based in Salt Lake City, Utah.

MYGN Articles

Wednesday's top analyst upgrades and downgrades included Chevron, Cleveland-Cliffs, Infosys, Knight-Swift Transportation, Microsoft, Nucor, Salesforce, Steel Dynamics, Wheaton Precious Metals and...
Thursday's top analyst upgrades and downgrades included Adobe, Apple, Conagra Brands, CrowdStrike, Fortinet, IBM, Mobileye Global, Morgan Stanley, Oatly, Oracle, PayPal, Seagate Technology, Shopify...
Friday's top analyst upgrades and downgrades included Airbnb, Cleveland-Cliffs, CrowdStrike, Meta Platforms, Nasdaq, Okta, PENN Entertainment, PPL, Splunk, Target, U.S. Steel and Zscaler.
Friday's top analyst upgrades and downgrades included Applied Materials, Autodesk, Bank of America, BP, Broadcom, Micron Technology, Morgan Stanley and Western Digital.
Alliance Data, Cimarex Energy, Myriad Genetics and Nestle were among Tuesday afternoon's analyst upgrades and downgrades.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Boston Beer, Carvana, HD Supply, Marathon Petroleum, Square, Trade Desk and Whirlpool.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators...
The top analyst upgrades, downgrades and initiations seen on Wednesday include Agilent Technologies, Alibaba, CRISPR Therapeutics, Iridium Communications, McDonald's, Myriad Genetics, Shake Shack and...
The top analyst upgrades, downgrades and initiations seen on Tuesday include Baker Hughes, CBS, Generac, Halliburton, Nike, PG&E, Snap, Tesla, Weatherford and Western Digital.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Amazon, Apple, BP, CSX, General Electric, Humana, Myriad Genetics, Mondelez, UnitedHealth and Vodafone.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Affimed, Coty, Cree, Lululemon Athletica, Myriad Genetics, Tesla and Xilinx.
The top analyst upgrades, downgrades and initiations seen from Wednesday include AT&T, CenturyLink, MercadoLibre, Netflix, Starbucks, Tiffany, TJX Companies and YRC Worldwide.
The top analyst upgrades, downgrades and other research calls from Wednesday include AT&T, Comcast, Hess, Netflix, Petrobras, Sirius XM, Texas Instruments, Verizon and Walt Disney.
The top analyst upgrades, downgrades and other research calls from Wednesday include Applied Materials, Celgene, Children's Place, Kinder Morgan, Match, Myriad Genetics, Nordstrom and Oracle.